Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

Blood Glucose SARS-CoV-2 Blood Glucose Self-Monitoring Pneumonia, Viral COVID-19 Angiotensin-Converting Enzyme Inhibitors Comorbidity COVID-19 Drug Treatment 3. Good health Coronavirus Betacoronavirus 03 medical and health sciences 0302 clinical medicine Cardiovascular Diseases Risk Factors Diabetes Mellitus Humans Coronavirus Infections Pandemics
DOI: 10.2337/dc20-0941 Publication Date: 2020-05-14T18:19:06Z
ABSTRACT
People with diabetes compared people without exhibit worse prognosis if affected by coronavirus disease 2019 (COVID-19) induced the severe acute respiratory syndrome 2 (SARS-CoV-2), particularly when compromising metabolic control and concomitant cardiovascular disorders are present. This Perspective seeks to explore newly occurring cardio-renal-pulmonary organ damage or aggravated process of COVID-19 its implications for risk management diabetes, especially taking into account potential interactions mechanisms cellular intrusion SARS-CoV-2. Severe infection SARS-CoV-2 can precipitate myocardial infarction, myocarditis, heart failure, arrhythmias as well an distress renal failure. They may evolve along multiorgan failure directly due SARS-CoV-2–infected endothelial cells resulting endotheliitis. complex pathology bear challenges use most medications in terms emerging contraindications that need close monitoring all diagnosed infection. Whenever possible, continuous glucose should be implemented ensure stable compensation. Patients intensive care unit requiring therapy glycemic handled solely intravenous insulin using exact dosing a perfusion device. Although not only ACE inhibitors angiotensin receptor blockers but also SGLT2 inhibitors, GLP-1 agonists, pioglitazone, probably seem increase number ACE2 receptors on utilized penetration, no evidence presently exists shows this might harmful acquiring worsening COVID-19. In conclusion, related profoundly affect diabetes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (58)
CITATIONS (66)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....